See more : Jianglong Shipbuilding Co., Ltd. (300589.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Provention Bio, Inc. (PRVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Provention Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Metallis Resources Inc. (MTS.V) Income Statement Analysis – Financial Results
- Emperor Metals Inc. (EMAUF) Income Statement Analysis – Financial Results
- Gladstone Land Corporation (LAND) Income Statement Analysis – Financial Results
- Public Joint Stock Company Interregional Distribution Grid Company of Siberia (MRKS.ME) Income Statement Analysis – Financial Results
- Psyence Group Inc. (PSYG.CN) Income Statement Analysis – Financial Results
Provention Bio, Inc. (PRVB)
About Provention Bio, Inc.
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 12.90M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 512.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 12.38M | 1.40M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 96.03% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 75.80M | 69.63M | 66.36M | 36.36M | 22.65M | 7.68M |
| General & Administrative | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 64.11M | 47.35M | 33.33M | 8.01M | 4.17M | 1.46M |
| Other Expenses | 627.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 140.54M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Cost & Expenses | 141.06M | 116.97M | 99.69M | 44.37M | 26.81M | 9.14M |
| Interest Income | 2.24M | 146.00K | 583.00K | 1.09M | 669.00K | 131.50K |
| Interest Expense | 1.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.47M | 387.00K | 33.00K | -16.00K | 149.00K | 6.50K |
| EBITDA | -124.69M | -115.58M | -99.69M | -44.37M | -26.67M | -9.13M |
| EBITDA Ratio | -966.98% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -128.16M | -115.58M | -99.69M | -44.37M | -26.81M | -9.14M |
| Operating Income Ratio | -993.88% | -8,285.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.20M | 146.00K | 583.00K | 1.09M | 149.00K | 6.50K |
| Income Before Tax | -126.96M | -115.43M | -99.10M | -43.29M | -26.67M | -9.13M |
| Income Before Tax Ratio | -984.54% | -8,274.70% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -13.39M | -1.00M | -523.00K | -1.09M | -187.00K | -131.50K |
| Net Income | -113.57M | -114.43M | -98.58M | -42.20M | -26.48M | -9.13M |
| Net Income Ratio | -880.69% | -8,203.01% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| EPS Diluted | -1.52 | -1.81 | -1.88 | -1.04 | -1.18 | -0.27 |
| Weighted Avg Shares Out | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
| Weighted Avg Shares Out (Dil) | 74.72M | 63.10M | 52.46M | 40.75M | 22.44M | 33.88M |
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.
The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB
Why Provention Bio Stock Skyrocketed 256% This Week
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVB
This biopharma stock jumped over 250% on Monday: what happened?
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
Shareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with Sanofi
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
Source: https://incomestatements.info
Category: Stock Reports